2.22
+0.05(+2.30%)
Currency In USD
| Previous Close | 2.17 |
| Open | 2.16 |
| Day High | 2.25 |
| Day Low | 2.04 |
| 52-Week High | 6.9 |
| 52-Week Low | 1.69 |
| Volume | 43,444 |
| Average Volume | 103,733 |
| Market Cap | 5.73M |
| PE | -0.78 |
| EPS | -2.84 |
| Moving Average 50 Days | 2.97 |
| Moving Average 200 Days | 2.77 |
| Change | 0.05 |
If you invested $1000 in Creative Medical Technology Holdings, Inc. (CELZ) 10 years ago, it would be worth $0.27 as of December 25, 2025 at a share price of $2.22. Whereas If you bought $1000 worth of Creative Medical Technology Holdings, Inc. (CELZ) shares 5 years ago, it would be worth $113.85 as of December 25, 2025 at a share price of $2.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
GlobeNewswire Inc.
Dec 17, 2025 2:15 PM GMT
Completion of Enrollment Positions CELZ for Near-Term Data Catalysts and Accelerates Path Toward Commercialization of a Transformative, Non-Opioid Therapy for Chronic Lower Back PainPHOENIX, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Techno
Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201
GlobeNewswire Inc.
Dec 02, 2025 2:15 PM GMT
Global assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel’s advancement across large unmet-need global marketsPHOENIX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Creative Medical Techno
Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits
GlobeNewswire Inc.
Oct 30, 2025 1:15 PM GMT
Selects Greenstone Biosciences to Accelerate AI-Driven iPSC Precision Medicine PlatformPHOENIX, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage lead